Bleeding Disorder News and Research

RSS

Bayer launches unique fitness program for hemophilia A children

Bayer HealthCare is introducing a fitness program to help children ages 7-12 and young adults ages 13-16 with hemophilia A live active lives. "Living Fit! A Joint Effort" is a unique strength training, fitness and wellness program created to increase awareness of the importance of exercise and nutrition among this population and their caregivers.

27 Oct 2010

European Commission grants orphan drug status to OBI-1 for hemophilia treatment

Inspiration Biopharmaceuticals, Inc. announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia.

20 Oct 2010

Octapharma USA launches wilate replacement therapy Web site for von Willebrand Disease

Octapharma USA has launched a comprehensive Web site for wilate® at www.wilateusa.com to provide von Willebrand disease healthcare professionals and patients with easily accessible information, news and updates. The U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate® (von Willebrand Factor/Factor VIII Concentrate, Human), the first replacement therapy developed specifically for von Willebrand Disease (VWD).

5 Oct 2010

Researchers develop new animal model for studying hemophilia A

Researchers at Yale School of Medicine have developed a new animal model for studying hemophilia A, with the goal of eventually treating people with the disorder.

3 Sep 2010

NovoSeven RT in 8 mg vial for hemophilia A or B with inhibitors receives FDA approval

Novo Nordisk announced today that the U.S. Food and Drug Administration has approved NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) in an 8 mg vial size, making the hemophilia A or B with inhibitors treatment available in 1, 2, 5 and 8 mg vials. The 8 mg vial allows a rapid initiation and administration of this medication for those patients who need a larger dose. In addition, FDA has also approved the extension of shelf life for all vial sizes from 24 months to 36 months at room temperature (at or below 77 degrees Fahrenheit).

11 Aug 2010

Octapharma USA receives confirmation of orphan drug exclusivity from FDA for wilate

Octapharma USA has received confirmation of orphan drug exclusivity from the U.S. Food and Drug Administration for wilate (von Willebrand Factor/Factor VIII Concentrate, Human), the replacement therapy developed specifically for von Willebrand Disease. The approval comes from the FDA Office of Orphan Products Development, which helps to advance the development of products that demonstrate promise for the treatment of rare diseases.

2 Aug 2010

Ipsen, Inspiration receive positive opinion in Europe for orphan drug status of OBI-1 in treatment of hemophilia

Ipsen and Inspiration Biopharmaceuticals, Inc. announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency has issued a positive opinion on the granting of orphan drug status for OBI-1 for the treatment of hemophilia.

17 Jun 2010

NYBC urges community to donate blood in recognition of Mother's Day

New York Blood Center and its divisions serving the 20 million people of New York City, Long Island, the Hudson Valley, and New Jersey call upon the community to please donate blood in recognition of Mother's Day and families everywhere who are brought together by lives saved through the selfless gifts given by blood donors.

4 May 2010

Alair Bronchial Thermoplasty System receives FDA approval to treat asthma in adults

The U.S. Food and Drug Administration today approved the first medical device that uses radiofrequency energy to treat severe and persistent asthma in certain adults.

28 Apr 2010

AMT initiates dosing in Phase I/II gene therapy clinical trial for hemophilia B

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease.

10 Mar 2010

Scientists discover genetic cause of Quebec Platelet Disorder

For some Canadians, any cut such as from dental work or surgery can cause days or more of bleeding. Although they are not hemophiliacs, for some an ordinary bruise can balloon into the size of an orange.

4 Mar 2010

Gene therapy for LCA clears another hurdle: Study

Gene therapy for a severe inherited blindness, which produced dramatic improvements last year in 12 children and young adults who received the treatment in a clinical trial, has cleared another hurdle. The same research team that conducted the human trial now reports that a study in animals has shown that a second injection of genes into the opposite, previously untreated eye is safe and effective, with no signs of interference from unwanted immune reactions following the earlier injection.

4 Mar 2010

FDA warns about drug mix-ups; drug maker agrees to name change to avoid confusion

The U.S. Food and Drug Administration today warned consumers about the potential for serious side effects from mistakenly using Maalox Total Relief instead of other Maalox products. The two products are intended for the relief of different symptoms and contain different active ingredients.

18 Feb 2010

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

16 Feb 2010

Ipsen enters into partnership agreement with Inspiration Biopharmaceuticals

Ipsen and Inspiration Biopharmaceuticals, Inc. (Inspiration) today announced that they have entered into a partnership to create a world leading hemophilia franchise. The partnership is designed to leverage combined expertise and resources to advance a broad portfolio of recombinant proteins, which address all major hemophilia disorders in a unique way by focusing on two significant unmet needs: wider access to treatment with coagulation factors and treatment for inhibitor complications.

21 Jan 2010

FDA grants orphan drug exclusivity approval for Octapharma AG's wilate

Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilate® from the U.S. Food and Drug Administration (FDA).

18 Jan 2010

CSL Behring awards four advocacy grants to patient organizations in the U.S.

CSL Behring, a global leader in the plasma-protein biotherapies industry and a subsidiary of CSL Limited, has awarded four advocacy grants totaling $87,000 to patient organizations in the United States through the Local Empowerment for Advocacy Development (LEAD) program.

29 Dec 2009

McMaster University launches first online interactive educational program on bleeding disorders

McMaster University, in partnership with the Canadian Hemophilia Society and Bayer HealthCare Pharmaceuticals, has launched Canada's first online, interactive educational program on bleeding disorders. The program, Emergency Management of Bleeding Disorders, is available free to all Canadian health professionals to learn about the signs, symptoms, diagnosis and treatment of bleeding disorders.

10 Dec 2009

Wyeth pledges more than 40 million IUs of factor concentrates to WFH

As part of its continued commitment to hemophilia care around the world, Wyeth, now a part of Pfizer, has pledged more than 40 million international units (IUs) of factor concentrates to the World Federation of Hemophilia (WFH).

3 Dec 2009

Lysteda tablets to treat menorrhagia approved by the FDA

The U.S. Food and Drug Administration today approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps blood to clot.

24 Nov 2009